Although the revenue and EPS for Zai Lab Limited (ZLAB) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall ...

In this article, we are going to take a look at where Zai Lab Limited (NASDAQ:ZLAB) stands against other best breakout stocks to buy according to analysts. Stock markets have been on edge in ...

“In the first quarter, we continued to advance both our global pipeline and commercial business,” said Dr. Samantha Du, Founder, Chairperson, and CEO of Zai Lab. “We are rapidly expanding ...

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has accepted the ...

--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) will present new data from studies evaluating two of its internally developed, next-generation, investigational oncology therapies ...

For the quarter ended March 2025, Zai Lab Limited Unsponsored ADR (ZLAB) reported revenue of $106.49 million, up 22.2% over the same period last year. EPS came in at -$0.45, compared to -$0.55 in ...

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience ...